ODTX Nan (ln) Li bought Odyssey Therapeutics, Inc. shares — SEC Form 4BUYOdyssey Therapeutics, Inc.

The stock is trading at $17.23, down 14.62% from its 52-week high of $20.18, indicating a pullback from recent highs. The current price sits 10.66% above the 52-week low of $15.57.

• •Q2 2026 earnings on June 30, 2026, which showed a net loss of US$52.79 million and a loss per share of US$1.74.
• •Upcoming collaboration with Evotec announced on August 7, 2026, to leverage AI-enabled R&D capabilities.
• •The company raised $454 million in its IPO on May 11, 2026, though both Odyssey and Mobia traded lower in their debuts.

• •The company reported a net loss of US$52.79 million for Q2 2026, significantly higher than the US$41.24 million loss a year earlier.
• •The stock is trading at a forward P/E of -4.76, indicating negative earnings expectations.